LONDON (ShareCast) - (Sharecast News) - Medical device company Creo continued to trade in-line with expectations during 2019, while also making progress in the commercialisation of its CROMA Advanced Energy Platform and a suite of patented electrosurgical devices.
Creo generated initial revenues from its Speedboat device in 2019, the first in a range of gastrointestinal devices to be cleared for use with CROMA.

The AIM-listed firm also said on Thursday that progress in gaining regulatory approvals for a further four devices was "well advanced".

Looking ahead, Creo expects to see "significant growth" during 2020 in commercial orders for its Speedboat device, as it looks to manufacture early production in-house as processes were optimised ahead of outsourcing capacity.

Chief executive Craig Guilliford said: "Having delivered initial revenues last year, the next few months mark a significant step up for the business.

"With much appreciated shareholder support, we now have a unique opportunity with game changing devices to develop the business."

As of 1050 GMT, Creo shares were up 1.14% at 177p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE